Antifungal susceptibilities and identification of species of the Sporothrix schenckii complex isolated in Brazil

• Published in: Medical mycology (Oxford) Vol. 52; no. 1; p. 56
• Main Authors: Ottonelli Stopiglia, Cheila Denise, Magagnin, Cibele Massotti, Castrillón, Mauricio Ramírez, Mendes, Sandra Denise Camargo, Heidrich, Daiane, Valente, Patricia, Scroferneker, Maria Lúcia
• Format: Journal Article
• Language: English
• Published: England 01.01.2014
• Subjects: Antifungal Agents - pharmacology; Brazil; Humans; Microbial Sensitivity Tests; Molecular Typing; Mycological Typing Techniques; Sporothrix - classification; Sporothrix - genetics; Sporothrix - isolation & purification; Sporothrix - physiology; Sporotrichosis - microbiology; Brazil; Sporothrix; sporotrichosis; antifungal agents
• ISSN: 1460-2709
• DOI: 10.3109/13693786.2013.818726

Sporotrichosis is a subacute or chronic mycosis caused worldwide by the dimorphic species complex, Sporothrix schenckii. We studied 85 isolates recovered in Brazil to verify their identification and evaluate their in vitro antifungal susceptibility patterns. Based on phenotypic tests (microscopic features, ability to grow at 30°C and 37°C, colony diameters, as well as assimilation of sucrose and raffinose) and molecular assays (amplification of a fragment of the calmodulin gene), the strains were identified as S. schenckii, S. brasiliensis and S. globosa, with a predominance of S. schenckii isolates. There was 37.7% disagreement between the phenotypic and genotypic identification methodologies. In general, terbinafine was the most active drug, followed by ketoconazole and itraconazole, and the less active fluconazole and voriconazole. Five isolates (one S. globosa and four S. schenckii) were found to be itraconazole-resistant strains but, in general, there were no differences in the in vitro antifungal susceptibility profiles among the Sporothrix species.